文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌近距离放疗或高强度聚焦超声后12个月内导致住院的并发症:基于法国PMSI-MCO数据库2019至2020年数据的全国性研究

Complications leading to hospitalisation 12 months after brachytherapy or high-intensity focused ultrasound for localized prostate cancer: French national from the PMSI-MCO data, 2019 and 2020.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-09-12

该研究利用法国PMSI-MCO国家数据库回顾性分析了2019至2020年接受近距离放疗或高强度聚焦超声(HIFU)治疗的局限性前列腺癌患者,比较治疗后12个月内因并发症住院的原因。共纳入3090例患者,其中近距离放疗1699例、HIFU 1391例。HIFU后住院发生率远高于近距离放疗,尤其梗阻性并发症(12.94% vs 2.77%)、感染(8.20% vs 1.47%)和出血(6.76% vs 2.18%)导致住院的差异较大;大多数并发症发生在初次住院期间(HIFU 12%,近距离放疗1.4%)。

要点

  • HIFU后因梗阻性并发症住院率为12.94%,近距离放疗为2.77%。
  • HIFU后因感染住院率为8.20%,近距离放疗为1.47%。
  • HIFU后因出血住院率为6.76%,近距离放疗为2.18%。

核心结论

  • 在局限性前列腺癌治疗后一年内,HIFU后并发症比近距离放疗后更频繁,且两种治疗导致住院的原因不同,这些差异需在治疗策略及治疗后管理中予以考虑。

研究设计与样本

  • 回顾性研究,利用法国PMSI-MCO国家数据库分析2019年和2020年接受近距离放疗或HIFU治疗的局限性前列腺癌患者记录,共纳入3090例,其中近距离放疗1699例、HIFU 1391例。

主要发现

  • HIFU后住院发生率远高于近距离放疗,梗阻性并发症导致住院率HIFU 12.94% vs 近距离放疗2.77%。
  • 感染导致住院率HIFU 8.20% vs 近距离放疗1.47%,出血导致住院率HIFU 6.76% vs 近距离放疗2.18%。
  • 大多数并发症发生在初次住院期间:HIFU为12%,近距离放疗为1.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Prostate cancer can be treated using either brachytherapy or high-intensity focused ultrasound (HIFU), which are less invasive than surgery. Although both approaches have proved effective, few studies have looked at the specific causes of hospitalisation due to complications, following these treatments. The aim of this study was to compare the causes of hospitalisation. METHODS: A retrospective study was carried out examining the records of patients who had undergone brachytherapy or HIFU treatment for localized prostate cancer in 2019 and 2020, using the French national database: Programme de Médicalisation du Système d'Information - Médecine, Chirurgie, Obstétrique (PMSI-MSO). Data on post-treatment hospitalisations were analyzed. RESULTS: 3090 patients were included in the study, of whom 1699 underwent brachytherapy and 1391 HIFU procedures. The incidence of hospitalisation was much higher after HIFU than after brachytherapy, notably due to a higher rate of obstructive complications (12.94% vs 2.77%). Large differences were also found for infections (8.20% vs 1.47%) and bleeding (6.76% vs 2.18%) leading to hospitalisation. Most of the complications occurred at the initial hospitalization: 12% for HIFU, and 1.4% for brachytherapy. CONCLUSION: Complications were more frequent after treatment with HIFU than with brachytherapy in the year following treatment for localized prostate cancer. Further the causes of hospitalisation differed between the two treatments. These differences need to be taken into account in the therapeutic strategy, as well as in post-treatment management.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bourgarit T, Larose C, Dagry A, et al. Complications leading to hospitalisation 12 months after brachytherapy or high-intensity focused ultrasound for localized prostate cancer: French national from the PMSI-MCO data, 2019 and 2020. Clin Transl Radiat Oncol. 2024. PMID: 39381626. doi:10.1016/j.ctro.2024.100854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。